126 related articles for article (PubMed ID: 38641908)
1. Statement of Retraction: MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4.
Bioengineered; 2024 Dec; 15(1):2340165. PubMed ID: 38641908
[No Abstract] [Full Text] [Related]
2. Statement of Retraction: MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4.
Bioengineered; 2024 Dec; 15(1):2302650. PubMed ID: 38299340
[No Abstract] [Full Text] [Related]
3. Retracted article: MYCN contributes to the sensitization of acute myelogenous leukemia cells to cisplatin by targeting SRY-box transcription factor 4.
Huang X; Qi L; Lu W; Li Z; Li W; Li F
Bioengineered; 2024 Dec; 15(1):1997697. PubMed ID: 34709111
[TBL] [Abstract][Full Text] [Related]
4. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
Liu HJ; Li GL; Lei PC
Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
[No Abstract] [Full Text] [Related]
5. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
6. Acute myelogenous leukemia-derived SMAD4 mutations target the protein to ubiquitin-proteasome degradation.
Yang L; Wang N; Tang Y; Cao X; Wan M
Hum Mutat; 2006 Sep; 27(9):897-905. PubMed ID: 16865698
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of MYCN promotes proliferation of non-small cell lung cancer.
Liu K; Wang S; Liu Y; Gu J; Gu S; Xu Z; Zhang R; Wang Z; Ma H; Chen Y; Ji L
Tumour Biol; 2016 Sep; 37(9):12855-12866. PubMed ID: 27449038
[TBL] [Abstract][Full Text] [Related]
8. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
9. Statement of Retraction: Long non-coding RNA muscleblind like splicing regulator 1 antisense RNA 1 (LncRNA MBNL1-AS1) promotes the progression of acute myocardial infarction by regulating the microRNA-132-3p/SRY-related high-mobility-group box 4 (SOX4) axis.
Bioengineered; 2024 Dec; 15(1):2299561. PubMed ID: 38376423
[No Abstract] [Full Text] [Related]
10. Statement of Retraction: Long noncoding RNA LINC00339 promotes the oncogenicity of gastric cancer by regulating SRY-box 9 expression via sponging of microRNA-539.
Cell Cycle; 2021 Dec; 20(24):2665. PubMed ID: 34468266
[No Abstract] [Full Text] [Related]
11. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
Murphy DM; Buckley PG; Bryan K; Das S; Alcock L; Foley NH; Prenter S; Bray I; Watters KM; Higgins D; Stallings RL
PLoS One; 2009 Dec; 4(12):e8154. PubMed ID: 19997598
[TBL] [Abstract][Full Text] [Related]
12. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia.
Lei H; Xu HZ; Shan HZ; Liu M; Lu Y; Fang ZX; Jin J; Jing B; Xiao XH; Gao SM; Gao FH; Xia L; Yang L; Liu LG; Wang WW; Liu CX; Tong Y; Wu YZ; Zheng JK; Chen GQ; Zhou L; Wu YL
Nat Commun; 2021 Jan; 12(1):51. PubMed ID: 33397955
[TBL] [Abstract][Full Text] [Related]
13. MYCN transgenic zebrafish model with the characterization of acute myeloid leukemia and altered hematopoiesis.
Shen LJ; Chen FY; Zhang Y; Cao LF; Kuang Y; Zhong M; Wang T; Zhong H
PLoS One; 2013; 8(3):e59070. PubMed ID: 23554972
[TBL] [Abstract][Full Text] [Related]
14. Low expression of MYCN promotes cisplatin resistance by suppressing cisplatin-induced apoptosis in epithelial ovarian cancer.
Yu R; Zhang H; Wang R; Xiao L
Oncol Lett; 2022 Dec; 24(6):423. PubMed ID: 36284653
[TBL] [Abstract][Full Text] [Related]
15. TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
Tan SH; Tan TK; Yokomori R; Liao M; Huang XZ; Yeoh AEJ; Sanda T
Leukemia; 2023 Oct; 37(10):1969-1981. PubMed ID: 37591943
[TBL] [Abstract][Full Text] [Related]
16. Structure-function relationships in human testis-determining factor SRY: an aromatic buttress underlies the specific DNA-bending surface of a high mobility group (HMG) box.
Racca JD; Chen YS; Maloy JD; Wickramasinghe N; Phillips NB; Weiss MA
J Biol Chem; 2014 Nov; 289(47):32410-29. PubMed ID: 25258310
[TBL] [Abstract][Full Text] [Related]
17. Low SOX12 Expression Is Correlated With Poor Prognosis in Patients With Gastric Cancer.
Yang KK; Xu HM; Huang JY; Guo YX; Wang ZN
Technol Cancer Res Treat; 2020; 19():1533033819901126. PubMed ID: 32019439
[TBL] [Abstract][Full Text] [Related]
18. Differences in the DNA-binding properties of the HMG-box domains of HMG1 and the sex-determining factor SRY.
Teo SH; Grasser KD; Thomas JO
Eur J Biochem; 1995 Jun; 230(3):943-50. PubMed ID: 7601157
[TBL] [Abstract][Full Text] [Related]
19. Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer.
Faller BA; Robu VG; Borghaei H
Clin Lung Cancer; 2009 Nov; 10(6):438-40. PubMed ID: 19900863
[TBL] [Abstract][Full Text] [Related]
20. Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
Murphy DM; Buckley PG; Das S; Watters KM; Bryan K; Stallings RL
PLoS One; 2011; 6(6):e21436. PubMed ID: 21731748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
